Genomic influences on schizophrenia-related neurotransmitter systems

Journal of Nursing Scholarship

Volumn 37, Issue 4, 2005, Pages 322-328

  Keltner, Norman L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Dopamine; Genetics; Polymorphisms; Receptors; Schizophrenia; Serotonin

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE RECEPTOR; SEROTONIN; SEROTONIN RECEPTOR;

GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; NOMENCLATURE; REVIEW; SCHIZOPHRENIA;

CATECHOL O-METHYLTRANSFERASE; DOPAMINE; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN; TERMINOLOGY;

EID: 33644864090     PISSN: 15276546     EISSN: 15475069     Source Type: Journal    
DOI: 10.1111/j.1547-5069.2005.00056.x     Document Type: Review

References (38)

1. Abdolmaleky, H.M., Faraone, S.V., Glatt, S.J., & Tsuang, M.T. (2004). Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophrenia Research, 67 (1 53 62.
2. American Psychiatric Association 1980). Diagnostic and statistical manual of mental disorders (3rd ed.). Washington, DC : Author.
3. Ayd, F.J., Jr. (1991). The early history of modern psychopharmacology. Neuropsychopharmacology, 5 (2 71 84.
4. Basile, V.S., Ozdemir, V., Masellis, M., Walker, M.L., Meltzer, H.Y., Lieberman, J.A. et al. 2000). A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia. Molecular Psychiatry, 5, 410 417.
5. Bartes-Faz, D., Junque, C., Serra-Grabulosa, J.M., Lopez-Alomar, A., Moya, A., Bargallo, N. et al. 2002). Dopamine DRD2 Taq1 polymorphism associates with caudate nucleus volume and cognitive performance in memory impaired subjects. Neuroreport, 13 (9 1121 1125.
6. Cardno, A.G., & Gottesman, I.I. (2000). Twin studies of schizophrenia: From bow-and-arrow concordances to star wars Mx and functional genomics. American Journal of Medical Genetics, 97 (1 12 17.
7. Collins, F.S., Green, E.D., Guttmacher, A.E., & Guyer, M.S. (2003). A vision for the future of genomics research: A blueprint for the genomic era. Nature, 422 (6934 835 847.
8. Duan, J., Wainwright, M.S., Comeron, J.M., Saitou, N., Sanders, A.R., Gelernter, J. et al. 2003). Synonymous mutations in the human dopamine D2 (DRD2) affect mRNA stability and synthesis of the receptor. Human Molecular Genetics, 12 (3 205 216.
9. Ebstein, R.P., Macciardi, F., Heresco-Levi, U., Serretti, A., Blaine, D., Verga, M. et al. 1997). Evidence for an association between the dopamine D3 receptor gene DRD3 and schizophrenia. Human Heredity, 47 (1 6 16.
10. Eichhammer, P., Albus, M., Borrmann-Hassenbach, M., Schoeler, A., Putzhammer, A., Frick, U. et al. 2000). Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenia patients: A generalization of Steen's study on DRD3 and tardive dyskinesia. American Journal of Medical Genetics, 96 (2 187 191.
11. Gaser, C., Nenadic, I., Buchsbaum, B.R., Hazlett, E.A., & Buchsbaum, M.S. (2004). Ventricular enlargement in schizophrenia related to volume reduction of the thalamus, striatum, and superior temporal cortex. American Journal of Psychiatry, 161 (1 154 156.
12. Harrison, P.J., & Owen, M.J. (2003). Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet, 361 (9355 417 419.
13. Ichikawa, J., & Meltzer, H.Y. (1999). Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antispsychotic drugs. European Archives of Psychiatry and Clinical Neuroscience, 249 (suppl. 4 IV90 IV98.
14. Joober, R., Benkelfat, C., Brisebois, K., Toulouse, A., Turecki, G., Lal, S. et al. 1999). T102C polymorphism in the 5HT2A gene and schizophrenia: Relation to phenotype and drug response variability. Journal of Psychiatry & Neuroscience, 24 (2 141 146.
15. Kapur, S., & Seeman, P. (2001). Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. American Journal of Psychiatry, 158, 360 369.
16. Kim, Y.K., Lee, M.S., & Kwak, D.I. (1999). No association between schizophrenia and serotonin receptor type 2A gene in Korea. Psychiatric Genetics, 9, 47 49.
17. Laraia, M.T. (2005). Psychopharmaogenetics: The first genetic test for psychopharmacology has arrived. American Psychiatric Nurses Association News, 17 (3 11 13.
18. Lesch, K.P., Balling, U., Gross, J., Strauss, K., Wolozin, B.L., Murphy, D.L. et al. 1994). Organisation of the human serotonin transporter gene. Journal of Neural Transmission, 95, 157 162.
19. Malhotra, A.K., Murphy, G.M. Jr., & Kennedy, J.L. (2004). Pharmacogenetics of psychotropic drug response. American Journal of Psychiatry, 161 (5 780 796.
20. Mata, I., Arranz, M.J., Lai, T., Mancama, D., Arrondo, J., Beperet, M. et al. 2002). The serotonergic system influences individual's response to resperidone. American Journal of Medical Genetics, 114, 728.
21. Mihara, K., Suzuki, A., Kondo, T., Yasui-Furukori, N., Ono, S., Otani, K. et al. 2001). Relationship between Taq1 A dopamine D2 receptors (DRD2) polymorphism and prolactin response to bromperidol. American Journal of Medical Genetics, 105 (3 271 274.
22. Miller, M.C. (2005). The biology of child maltreatment. Harvard Mental Health Letter, 21 (12 1 3.
23. Nolan, K.A., Volavka, J., Czobor, P., Cseh, A., Lachman, H., Saito, T. et al. 2000). Suicidal behavior in patients with schizophrenia is related to COMT polymorphism. Psychiatric Genetics, 10 (3 117 124.
24. Pickar, D. (2003). Pharmacogenomics of psychiatric drug treatment. Psychiatric Clinics of North America, 26, 303 321.
25. Pooley, E.C., Houston, K., Hawton, K., & Harrison, P.J. (2003). Deliberate self-harm is associated with allelic variation in the tryptophan hydroxylase gene (TPH A779C), but not with polymorphism in five other serotonergic genes. Psychological Medicine, 33 (5 775 783.
26. Prows, C.A., & Prows, D.R. (2004). Medication selection by genotype. American Journal of Nursing, 104 (5 60 70.
27. Rujescu, D., Giegling, I., Bondy, B., Gietl, A., Zill, P., & Moller, H.J. (2002). Association of anger-related traits with SNPs in the TPH gene. Molecular Psychiatry, 7 (9 1023 1029.
28. Seeman, P., & Van Tol, H.H.M. (1994). Dopamine receptor pharmacology. Trends in Pharmacological Science, 15 (7 264 270.
29. Siever, L.J., & Davis, K.L. (2004). The pathophysiology of schizophrenia disorders: Perspectives from the spectrum. American Journal of Psychiatry, 161 (3 398 413.
30. Stahl, S.M. (2000). Essential psychopharmacology (2nd ed). New York : Cambridge University Press.
31. Suzuki, A., Mihara, K., Kondo, T., Nagashima, U., Otani, K., & Kaneko, S. (2000). The relationship between dopamine D2 receptor polymorphism at Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics, 10, 335 341.
32. Torrey, E.F., & Yolken, R.H. (1995). Could schizophrenia be a viral zoonosis transmitted from house cats? Schizophrenia Bulletin, 21 (2 167 171.
33. Uhl, G.R., & Grow, R.W. (2004). The burden of complex genetics in brain disorders. Archives of General Psychiatry, 61, 223 229.
34. Wei, J., & Hemmings, G.P. (1999). Lack of evidence for association between COMT locus and schizophrenia. Psychiatric Genetics, 9, 183 186.
35. Weinberger, D.R. (1987). Implications of normal brain for the pathogenesis of schizophrenia. Archives of General Psychiatry, 44, 660 669.
36. Weinshilboum, R. (2003). Inheritance and drug response. New England Journal of Medicine, 348 (6 529 537.
37. Williams, M. (2003). Genome-based drug discovery: Prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia. Current Opinion in Investigational Drugs, 4 (1 31 36.
38. Wilson, M. (1993). DSM-III and the transforming of American Psychiatry: A history. American Journal of Psychiatry, 150 (3 399 410.